Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Non-canonical ALK7 pathways promote pancreatic cancer metastasis through β-catenin/MMP-mediated basement membrane breakdown and intravasation

ABSTRACT: Breaching the vascular barrier is a critical step in pancreatic ductal adenocarcinoma (PDAC) metastasis, yet the mechanisms enabling this process to remain incompletely understood. This study identifies two distinct but interconnected ALK7-driven non-canonical pathways that promote PDAC dissemination. The ALK7–β-catenin–EMT axis enhances intrinsic tumor cell motility, driving epithelial–mesenchymal transition (EMT) and cytoskeletal remodeling. In parallel, the ALK7–β-catenin–MMP axis facilitates metastatic invasion by upregulating MMP production, leading to ECM degradation and invadosome formation, which promote vascular barrier breakdown. An orthotopic PDAC metastasis model reveals that both pharmacological and genetic ALK7 inhibition suppresses lung metastasis, emphasizing its role in facilitating tumor invasion. A 3D microfluidic vessel-on-chip platform further demonstrates that ALK7 inhibition preserves basement membrane (BM) integrity, limiting intravasation without affecting extravasation. While MMP inhibition effectively blocks BM breakdown and intravasation, extravasation remains unaffected, highlighting distinct molecular requirements for different metastatic stages. These findings establish ALK7 as a dual-function pro-metastatic regulator that orchestrates both tumor cell plasticity and ECM remodeling, positioning ALK7 inhibition as a promising strategy to target early metastatic dissemination in PDAC.

ORGANISM(S): Mus musculus

PROVIDER: GSE290145 | GEO | 2025/07/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Cancer Cell Extravasation Requires iPlectin Mediated Choreography of MT1-MMP at Invadopodia

Project description:Cancer cell extravasation is a key step of the metastatic cascade and an attractive therapeutic opportunity. Early steps in cancer cell extravasation require formation of tentacle-like protrusions called invadopodia that physically breach the endothelial barrier and degrade extracellular matrix (ECM). However, the mechanisms by which invadopodia-specific proteases such as MT1-MMP are called to invadopodia are unclear. In integrin-activated metastatic breast cancer cells, MT1-MMP was found to associate with plectin, a cytoskeletal linker protein, and vimentin, an intermediate filament (IF) protein. Interestingly, complex formation between plectin MT1-MMP immediately launches invadopodia formation, a subtype we termed iplectin (i=invadopodial). iPlectin (complexes of plectin and MT1-MMP) and vimentin cooperate to deliver and anchor this form of MT1-MMP to invadopodia. Genetic depletion of plectin significantly reduced invadopodia formation and significantly reduced cell invasion in vitro. To ascertain the effects of depleted plectin on metastatic behavior, in vivo extravasation efficiency assays and intravital imaging methods were performed. These assays revealed iplectin to be a key component of invadopodia ultrastructure; loss of plectin abrogated cancer cell extravasation rates. Pharmacological inhibition of plectin using the novel small molecule Plecstatin-1 (PST-1) altered vimentin and microtubule networks and altered MT1-MMP delivery to F-actin puncta, presumably due to inhibition of iplectin. In terms of metastasis dynamics, PST-1 treatment reduced invadopodia formation and extravasation rates. Hence, iplectin is responsible for MT1-MMP being called to invadopodia and the most therapeutically relevant form of plectin.

2025-03-28 | PXD039276 | Pride

RNA-seq of MMTV-Neu AXL KO tumors

Project description:AXL is activated by its ligand GAS6 and is expressed in triple-negative breast cancer cells. We report that AXL is also detected in HER2+ breast cancer specimens where its expression correlates with poor patients’ survival. Using murine models of HER2+ breast cancer, AXL, but not Gas6, was found essential for metastasis. We determined that AXL is required for intravasation, extravasation and growth at the metastatic site. AXL is expressed in HER2+ cancers displaying EMT signatures and contributes to sustain EMT in murine tumors. Interfering with AXL in patient-derived xenograft impaired TGF-β-induced cell invasion. Lastly, pharmacological inhibition of AXL decreased the metastatic burden of mice developing HER2+ breast cancer. Our data identify AXL as a potential co-therapeutic target during the treatment of HER2+ breast cancers to limit metastasis.

2018-05-01 | GSE102368 | GEO

RNA-seq of MMTV-Neu AXL KO tumor grafts in FVB

2018-05-01 | GSE102369 | GEO

Cell viscosity influences hematogenous dissemination and metastatic extravasation of tumor cells

Project description:Metastases arise from a multi-step process during which tumor cells change their mechanics in response to microenvironmental cues. While such mechanical adaptability could influence metastatic success, how tumor cell mechanics directly impacts intravascular behavior of circulating tumor cells (CTCs) remains poorly understood. In the present study, we demonstrate how the deformability of CTCs affects hematogenous dissemination and identify the mechanical profiles that favor metastatic extravasation. Combining intravital microscopy with CTC-mimicking elastic beads and mechanically-tuned tumor cells, we demonstrate that the inherent properties of circulating objects dictate their ability to enter constraining vessels. We identify cellular viscosity as the key property that governs CTC circulation and arrest patterns. We further demonstrate that cellular viscosity is required for efficient extravasation and find that properties that favor extravasation and subsequent metastatic outgrowth can be opposite. Altogether, we identify CTC viscosity as a key biomechanical parameter that shapes several steps of metastasis.

2024-11-24 | E-MTAB-14571 | biostudies-arrayexpress

Characterization of the ALK7 signaling pathway in PanNET, using cell lines that either express dominant negative ALK7 (ALK7-DN), or subjected to ALK7 knock-down (shALK7), treated with activin B

Project description:Herein we report that the TGFß superfamily receptor ALK7 is a suppressor of tumorigenesis and metastasis, as revealed by functional studies in mouse models of pancreatic neuroendocrine and luminal breast cancer, complemented by experimental metastasis assays. Activation in neoplastic cells of the ALK7 signaling pathway by its principal ligand activin B induces apoptosis. During tumorigenesis, cancer cells use two different approaches to evade this barrier, either downregulating activin B and/or ALK7. Suppressing ALK7 expression additionally contributes to the capability for metastatic seeding. ALK7 is associated with shorter relapse-free survival of various human cancers and distant-metastasis-free survival of breast cancer patients. This study introduces a new mechanistic insight into primary and metastatic tumor development, in the form of a protective barrier that triggers apoptosis in cells that are not ‘authorized’ to proliferate within a particular tissue, by virtue of those cells expressing ALK7 in a tissue microenvironment bathed in its ligand.

2019-05-06 | GSE103798 | GEO

Characterization of the ALK7 signaling pathway in PanNET, using cell lines that either express constitutively active ALK7 (ALK7-CA) or treated with activin B

2019-05-06 | GSE103796 | GEO

CdGAP is a Talin-binding protein and a target of TGF-β signaling that promotes HER2-positive breast cancer growth and metastasis

Project description:Epithelial-to-mesenchymal transition (EMT) plays a crucial role in metastasis, which is the leading cause of death in breast cancer patients. We show that Cdc42 GTPase-activating protein (CdGAP) promotes tumor formation and metastasis to lungs in the HER2-positive (HER2+) murine breast cancer model. CdGAP facilitates intravasation, extravasation, and growth at metastatic sites. CdGAP depletion in HER2+ murine primary tumors mediates crosstalk with a Dlc1-RhoA pathway and is associated with a transforming growth factor-β (TGF-β)-induced EMT transcriptional signature. To further delineate the molecular mechanisms underlying the pro-migratory role of CdGAP in breast cancer cells, we searched for CdGAP interactors by performing a proteomic analysis using HEK293 cells overexpressing GFP-CdGAP. We found that CdGAP interacts with the adaptor Talin to modulate focal adhesion dynamics and integrin activation. Moreover, HER2+ breast cancer patients with high CdGAP mRNA expression combined with a high TGF-β-EMT signature are more likely to present lymph node invasion. Our results suggest CdGAP as a candidate therapeutic target for HER2+ metastatic breast cancer by inhibiting TGF-β and Integrin/Talin signaling pathways.

2023-07-14 | PXD043376 | Pride

Collagenolysis dependent DDR1 signaling dictates pancreatic cancer outcome

Project description:Pancreatic ductal adenocarcinoma (PDAC) is a highly desmoplastic, aggressive cancer, frequently progressing and spreading by liver metastasis. Cancer-associated fibroblasts (CAF), extracellular matrix (ECM), and type I collagen (Col I) support or restrain PDAC progression and may impede blood supply and nutrient availability. The dichotomous role of the stroma in PDAC, and the mechanisms through which it influences patient survival and enables desmoplastic cancers to escape nutrient limitation remain poorly understood. Here we show that matrix metalloprotease (MMP)-cleaved or intact Col I (cCol I and iCol I, respectively) exert opposing effects on PDAC bioenergetics, macropinocytosis (MP), tumor growth and metastasis. While cCol I activates DDR1 (discoidin domain receptor-1)-NF-kB-p62-NRF2 signaling to promote PDAC growth, iCol I triggers DDR1 degradation and restrains PDAC growth. Patients whose tumors are iCol I enriched and DDR1 and NRF2 low have improved median survival compared to those with high cCol I, DDR1 and NRF2. Inhibition of DDR1-stimulated NF-kB or mitochondrial biogenesis blocked tumorigenesis in wildtype mice but not in mice expressing MMP-resistant Col I. The diverse effects of the tumor stroma on PDAC growth, metastasis, and patient survival are mediated through the Col I-DDR1-NF-kB-NRF2-mitochondrial biogenesis pathway, presenting new therapeutic opportunities.

2022-07-13 | GSE206218 | GEO

MetSearch: A screening platform for the discovery of genes implicated in metastatic dormancy and reactivation

Project description:We have developed a screening platform for the isolation of genetic entities involved in metastatic reactivation. Retroviral libraries encoding cDNAs from highly metastatic breast cancer cells or pooled microRNAs were transduced into breast cancer cells that become dormant upon infiltrating the lung. Upon inoculation in the tail vein of mice, the cells that had acquired the ability to undergo reactivation generated metastatic lesions. Integrated retroviral vectors were recovered from these lesions, sequenced, and subjected to a second round of validation. By using this strategy, we identified canonical genes and microRNAs that mediate metastatic reactivation in the lung. To identify genes that oppose reactivation, we screened an expression library encoding shRNAs and we identified target genes that encode potential enforcers of dormancy. Our screening strategy enables the identification and rapid biological validation of single genetic entities that are necessary to maintain dormancy or to induce reactivation. This technology should facilitate the elucidation of the molecular underpinnings of these processes. We conducte miRNA microarray analysis (Agilent Technologies) as a complementary technique to examine miRNA expression profiles in our tumor progression series model, comparing the non-metastatic cells lines (67NR, 168FARN, 4TO7) with that of the metastatic cell line (4T1). By studying these profiles, we can identify sets of miRNAs that regulate the different steps of metastasis, namely intravasation, survival in the circulatory system and at distant sites, and extravasation and metastases formation, as represented by the different cell lines.

2015-11-24 | E-GEOD-43483 | biostudies-arrayexpress

Expression data from mouse breast cancer tissue: Serglycin heterozygous and knock-out conditions

Project description:Serglycin proteoglycans contribute to proper storage and secretion of inflammatory mediators in hematopoietic cells. Serglycin is also expressed in cancer cells where increased expression has been linked to poor prognosis. In the present study we report that serglycin proteoglycan is absolutely required for metastasis in the MMTV-PyMT-driven mouse breast cancer model. Serglycin seems to play a role in promoting epithelial to mesenchymal transition, cancer-related inflammation and extravasation. Our results suggest that serglycin and serglycin-dependent mediators are potential drug targets to prevent metastatic disease/dissemination of cancer.

2016-06-01 | GSE67806 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data